Nuvectis Pharma Reports $6.1 Million Net Loss in Q1 2026

Nuvectis Pharma, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $6.1 million, an increase from the $5.3 million loss recorded in the same period of 2025. The company's operating loss for the quarter was $6.3 million, compared to a loss of $5.6 million in the prior year. The increase in losses is attributed to higher research and development expenses, which rose to $4.1 million from $3.7 million, driven primarily by increased manufacturing costs and employee compensation. General and administrative expenses also increased to $2.2 million from $1.9 million, reflecting higher professional and consulting service costs.

As of March 31, 2026, Nuvectis reported cash and cash equivalents of $25.1 million, a decrease from $31.6 million at the end of 2025. The company has not generated any revenue since its inception and continues to rely on capital raised through equity offerings to fund its operations. During the first quarter, Nuvectis raised approximately $7,000 through its At-the-Market (ATM) program, a significant decline compared to the $15.5 million raised in a public offering completed in February 2025. The company’s accumulated deficit has now reached $105.7 million.

Nuvectis remains focused on the development of its lead product candidate, NXP900, a SRC Family Kinase inhibitor. The company has made significant progress in its clinical trials, with the Phase 1 study initiated in September 2023. The study is designed to evaluate the safety and efficacy of NXP900 in treating various solid tumors. The company has also entered into a license agreement with the University of Edinburgh for the development and commercialization of NXP900, which includes potential milestone payments and royalties.

Operationally, Nuvectis has maintained a small workforce, with 12 full-time employees as of the end of the reporting period. The company anticipates that it will need to expand its team to support ongoing clinical trials and other operational needs. Looking ahead, Nuvectis expects to incur substantial expenses as it advances its clinical programs and seeks regulatory approvals for its product candidates. The company has indicated that it will require additional capital to fund these activities and has filed a shelf registration statement to facilitate future capital raises.

In summary, Nuvectis Pharma continues to navigate a challenging financial landscape as it develops its oncology-focused therapies. The company is actively pursuing clinical trials for NXP900 while managing its cash reserves and seeking additional funding to support its growth and operational objectives.